KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Notes Payables (2016 - 2021)

Abbott Laboratories (ABT) has disclosed Notes Payables for 13 consecutive years, with $197.0 million as the latest value for Q3 2021.

  • Quarterly Notes Payables fell 5.29% to $197.0 million in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $197.0 million through Sep 2021, down 5.29% year-over-year, with the annual reading at $213.0 million for FY2020, 5.97% up from the prior year.
  • Notes Payables hit $197.0 million in Q3 2021 for Abbott Laboratories, down from $199.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $341.0 million in Q2 2018 to a low of $197.0 million in Q3 2021.
  • Historically, Notes Payables has averaged $213.6 million across 5 years, with a median of $205.0 million in 2020.
  • Biggest five-year swings in Notes Payables: plummeted 92.46% in 2017 and later surged 56.42% in 2018.
  • Year by year, Notes Payables stood at $206.0 million in 2017, then decreased by 2.91% to $200.0 million in 2018, then grew by 0.5% to $201.0 million in 2019, then increased by 5.97% to $213.0 million in 2020, then dropped by 7.51% to $197.0 million in 2021.
  • Business Quant data shows Notes Payables for ABT at $197.0 million in Q3 2021, $199.0 million in Q2 2021, and $199.0 million in Q1 2021.